Infections with bacteria of the genus ACINETOBACTER.
A genus of gram-negative bacteria of the family MORAXELLACEAE, found in soil and water and of uncertain pathogenicity.
A species of gram-negative, aerobic bacteria, commonly found in the clinical laboratory, and frequently resistant to common antibiotics.
The ability of bacteria to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS).
A species of gram-negative, aerobic bacteria found in soil and water. Although considered to be normally nonpathogenic, this bacterium is a causative agent of nosocomial infections, particularly in debilitated individuals.
Substances that reduce the growth or reproduction of BACTERIA.
Any infection which a patient contracts in a health-care institution.
A group of beta-lactam antibiotics in which the sulfur atom in the thiazolidine ring of the penicillin molecule is replaced by a carbon atom. THIENAMYCINS are a subgroup of carbapenems which have a sulfur atom as the first constituent of the side chain.
Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.
Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses).
Enzymes found in many bacteria which catalyze the hydrolysis of the amide bond in the beta-lactam ring. Well known antibiotics destroyed by these enzymes are penicillins and cephalosporins.
Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.
Deoxyribonucleic acid that makes up the genetic material of bacteria.
Nonsusceptibility of bacteria to the action of the beta-lactam antibiotics. Mechanisms responsible for beta-lactam resistance may be degradation of antibiotics by BETA-LACTAMASES, failure of antibiotics to penetrate, or low-affinity binding of antibiotics to targets.
The ability of bacteria to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS).
Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)

Acinetobacter bacteremia in Hong Kong: prospective study and review. (1/737)

The epidemiological characteristics of 18 patients with acinetobacter bacteremia were analyzed. Patients (mean age, 55.5 years) developed bacteremia after an average of 14.1 days of hospitalization. Fifteen of 16 patients survived bacteremia caused by Acinetobacter baumannii. Cultures of blood from the remaining two patients yielded Acinetobacter lwoffii. Most patients (78%) resided in the general ward, while four patients (22%) were under intensive care. Genotyping by arbitrarily primed polymerase chain reaction analysis and the temporal sequence of isolation were more useful than phenotyping by antimicrobial susceptibility in the determination of the source of bacteremia, and the intravascular catheter was the leading infection source (39% of cases). The possibility of an association of glucose with the pathogenesis of acinetobacter infection was raised.  (+info)

Risk factors for nosocomial bloodstream infections due to Acinetobacter baumannii: a case-control study of adult burn patients. (2/737)

Risk factors for Acinetobacter baumannii bloodstream infection (BSI) were studied in patients with severe thermal injury in a burn intensive care unit where A. baumannii was endemic. Of 367 patients hospitalized for severe thermal injury during the study period, 29 patients with nosocomial A. baumannii BSI were identified (attack rate, 7.9%). Cases were compared with 58 matched controls without A. baumannii BSI. The overall mortality rate was 31% among cases and 14% among controls; only two deaths (7%) were considered directly related to A. baumannii BSI. Molecular typing of A. baumannii blood isolates by means of randomly amplified polymorphic DNA analysis and pulsed-field gel electrophoresis revealed the presence of three different strain types. Multivariate analysis showed that female gender (P = .027), total body surface area burn of > 50% (P = .016), prior nosocomial colonization with A. baumannii at a distant site (P = .0002), and use of hydrotherapy (P = .037) were independently associated with the acquisition of A. baumannii BSI in burn patients. These data underscore the need for effective infection control measures for this emerging nosocomial problem.  (+info)

Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. (3/737)

From March 1995 to March 1997, sulbactam was prospectively evaluated in patients with non-life-threatening multiresistant Acinetobacter baumannii infections. During this period, 47 patients were treated with sulbactam; of them, five were excluded because they had received < or =48 h of sulbactam therapy. A total of 42 patients, 27 males and 15 females with a mean age of 60+/-15 years, were finally evaluated. Infections were as follows: surgical wound, 19; tracheobronchitis, 12; urinary tract, 7; catheter-related bacteraemia, 2; and pneumonia, 2. Eighteen patients received intravenous sulbactam alone (1 g every 8 h) and 24 patients received intravenous sulbactam/ampicillin (1 g:2 g every 8 h) with no major adverse effects. Of the 42 patients, 39 improved or were cured and showed A. baumannii eradication and one patient had persistence of wound infection after 8 days of sulbactam/ampicillin requiring surgical debridement. Two patients died after 3 days of therapy (one of the deaths was attributable to A. baumannii infection). The in-vitro activity of the sulbactam/ampicillin combination was by virtue of the antimicrobial activity exhibited by sulbactam. Killing curves showed that sulbactam was bacteriostatic; no synergy was observed between ampicillin and sulbactam. Our results indicate that sulbactam may prove effective for non-life-threatening A. baumannii infections. Its role in the treatment of severe infections is unknown. However, the current formulation of sulbactam alone may allow its use at higher doses and provide new potential synergic combinations, particularly for those infections by A. baumannii resistant to imipenem.  (+info)

Identification of Acinetobacter baumannii strains with monoclonal antibodies against the O antigens of their lipopolysaccharides. (4/737)

Despite the emergence of Acinetobacter baumannii strains as nosocomial pathogens, simple methods for their phenotypic identification are still unavailable. Murine monoclonal antibodies specific for the O-polysaccharide moiety of the lipopolysaccharide (LPS) of two A. baumannii strains were obtained after immunization with heat-killed bacteria. The monoclonal antibodies were characterized by enzyme immunoassay and by Western and dot blot analyses and were investigated for their potential use for the identification of A. baumannii strains. The antibodies reacted with 46 of the 80 A. baumannii clinical isolates that were investigated, and reactivity was observed with 11 of 14 strains which were isolated during outbreaks in different northwestern European cities; no reactivity was observed with Acinetobacter strains of other genomic species, including the closely related genomic species 1 (Acinetobacter calcoaceticus), 3, and 13 sensu Tjernberg and Ursing, or with other gram-negative bacterial strains. The results show that O-antigen-specific monoclonal antibodies such as the ones described are convenient reagents which can be used to identify Acinetobacter strains in clinical and research laboratories.  (+info)

Some immunological properties of lipopolysaccharide from Acinetobacter baumannii. (5/737)

Acinetobacter baumannii, mainly biotype 9, is an important nosocomial opportunist pathogen in Chile and other countries. The biological basis of its virulence and prevalence is still unknown. As lipopolysaccharide (LPS) is often associated with virulence, some biological properties of purified LPS from seven nosocomial isolates, comprising four isolates of A. baumannii biotype 9, two isolates of biotype 8 and one isolate of biotype 1, were investigated. LPS was extracted and purified from each isolate by the hot phenol-water method, and its ability to elicit a mitogenic response and to induce the synthesis of a tumour necrosis factor (TNF-alpha) in mouse spleen cells was determined. Activity was evaluated in vivo by determining the splenic index in comparison with LPS from Salmonella Typhimurium. All seven LPS samples were mitogenic on the basis of cellular proliferation experiments and six induced synthesis of TNF-alpha. Similar results were obtained in in-vivo experiments in which LPS induced spleen cell growth, as shown by determination of the splenic index. These results suggest that the LPS of A. baumannii might contribute to the pathogenic properties of this species.  (+info)

Use of a murine O-antigen-specific monoclonal antibody to identify Acinetobacter strains of unnamed genomic species 13 Sensu Tjernberg and Ursing. (6/737)

A monoclonal antibody against the O-antigenic polysaccharide chain of the lipopolysaccharide (LPS) of Acinetobacter strains belonging to the unnamed genomic species 13 Sensu Tjernberg and Ursing (13TU) was obtained after immunization of BALB/c mice with heat-killed bacteria and was characterized by enzyme immunoassay and Western blot analysis, by use of LPS and proteinase K-treated bacterial lysates, analyses in which the antibody was shown to be highly specific for the homologous antigen. In addition, when tested in dot and Western blots, reactivity was observed with 9 of 18 Acinetobacter strains of genomic species 13TU which had been isolated in Germany and Denmark; no reactivity was observed with strains of other genomic species, including the closely related genomic groups 1 (A. calcoaceticus), 2 (A. baumannii), and 3 (unnamed), or with other gram-negative bacteria. The antibody described here represents a convenient reagent for the simple, economical, and accurate differentiation of clinical isolates of genomic species 13TU from other Acinetobacter strains. Although the antibody does not identify all isolates of this genomic group, it is evident that it will be a useful reagent in the development of a serotyping scheme for clinical laboratories.  (+info)

Genotypic and phenotypic similarity of multiresistant Acinetobacter baumannii isolates in the Czech Republic. (7/737)

The diversity of 103 clinical isolates of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex obtained between 1991 and 1997 from 17 Czech hospitals was studied by ribotyping, biotyping, plasmid profiling and antibiotic susceptibility testing. According to the EcoRI ribotypes, all but one of these isolates were identified to the DNA group level: 77 isolates were allocated to DNA group 2 (A. baumannii), 14 to DNA group 3, 10 to DNA group 13 sensu Tjernberg and Ursing and one to DNA group 1 (A. calcoaceticus). In total, 50 different EcoRI ribotypes and 10 biotypes were observed. Plasmids were found in 92% of the isolates and a high variability in plasmid profiles was found in isolates of the same DNA group. The combination of typing profiles allowed two predominant groups (termed A and B) to be distinguished among the A. baumannii isolates (37 and eight isolates, respectively) that shared a specific ribotype and were highly similar in other properties. These two groups comprised both sporadic and outbreak isolates and were found in most localities. Group A and B isolates were markedly more resistant to antibiotics than most of the remaining isolates, thus representing 85% of all multiresistant isolates. The features of groups A and B corresponded to those of two epidemic clones identified recently among hospital strains in north-western Europe.  (+info)

In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model. (8/737)

The effects of various regimens containing combinations of beta-lactams, beta-lactam inhibitor(s), and rifampin were assessed in a recently described mouse model of Acinetobacter baumannii pneumonia (M. L. Joly-Guillou, M. Wolff, J. J. Pocidalo, F. Walker, and C. Carbon, Antimicrob. Agents Chemother. 41:345-351, 1997). Two aspects of the therapeutic response were studied: the kinetics of the bactericidal effect (treatment was initiated 3 h after intratracheal inoculation, and bacterial counts were determined over a 24-h period) and survival (treatment was initiated 8 h after inoculation, and the cumulative mortality rate was assessed on day 5). Two clinical strains were used: a cephalosporinase-producing strain (SAN-94040) and a multiresistant strain (RCH-69). For SAN-94040 and RCH-69, MICs and MBCs (milligrams per liter) were as follows: ticarcillin, 32, 64, 256, and >256, respectively; ticarcillin-clavulanate, 32, 64, and 512, and >512, respectively; imipenem, 0.5, 0.5, 8, and 32, respectively; sulbactam, 0.5, 0.5, 8, and 8, respectively; and rifampin, 8, 8, 4, and 4, respectively. Against SAN-94040, four regimens, i.e., imipenem, sulbactam, imipenem-rifampin, and ticarcillin-clavulanate (at a 25/1 ratio)-sulbactam produced a true bactericidal effect (>/=3-log10 reduction of CFU/g of lung). The best survival rate (i.e., 93%) was obtained with the combination of ticarcillin-clavulanate-sulbactam, and regimens containing rifampin provided a survival rate of >/=65%. Against RCH-69, only regimens containing rifampin and the combination of imipenem-sulbactam had a true bactericidal effect. The best survival rates (>/=80%) were obtained with regimens containing rifampin and sulbactam. These results suggest that nonclassical combinations of beta-lactams, beta-lactamase inhibitors, and rifampin should be considered for the treatment of nosocomial pneumonia due to A. baumannii.  (+info)

Acinetobacter infections are caused by bacteria that can be found in various environments, such as soil, water, and healthcare facilities. These bacteria can cause a range of illnesses, from mild skin infections to serious respiratory and bloodstream infections. They are often resistant to multiple antibiotics, making them difficult to treat.

Acinetobacter baumannii is the species most commonly associated with human infection. It is known for its ability to survive on dry surfaces for extended periods of time, which can contribute to its spread in healthcare settings. Infections caused by Acinetobacter are a particular concern in critically ill patients, such as those in intensive care units, and in individuals with weakened immune systems.

Symptoms of an Acinetobacter infection depend on the site of infection but may include fever, cough, shortness of breath, wound drainage, or skin redness or swelling. Treatment typically involves the use of antibiotics that are still effective against the bacteria, which can be determined through laboratory testing. In some cases, infection control measures, such as contact precautions and environmental cleaning, may also be necessary to prevent the spread of Acinetobacter in healthcare settings.

'Acinetobacter' is a genus of gram-negative, aerobic bacteria that are commonly found in the environment, including water, soil, and healthcare settings. They are known for their ability to survive in a wide range of temperatures and pH levels, as well as their resistance to many antibiotics.

Some species of Acinetobacter can cause healthcare-associated infections, particularly in patients who are hospitalized, have weakened immune systems, or have been exposed to medical devices such as ventilators or catheters. These infections can include pneumonia, bloodstream infections, wound infections, and meningitis.

Acinetobacter baumannii is one of the most common species associated with human infection and is often resistant to multiple antibiotics, making it a significant public health concern. Infections caused by Acinetobacter can be difficult to treat and may require the use of last-resort antibiotics.

Preventing the spread of Acinetobacter in healthcare settings is important and includes practices such as hand hygiene, environmental cleaning, and contact precautions for patients with known or suspected infection.

'Acinetobacter baumannii' is a gram-negative, aerobic, coccobacillus-shaped bacterium that is commonly found in the environment, including water, soil, and healthcare settings. It is known to cause various types of infections in humans, particularly in hospitalized patients or those with weakened immune systems.

This bacterium can cause a range of infections, such as pneumonia, bloodstream infections, meningitis, and wound infections. 'Acinetobacter baumannii' is often resistant to multiple antibiotics, making it difficult to treat the resulting infections. This has led to its classification as a "superbug" or a multidrug-resistant organism (MDRO).

The medical community continues to research and develop new strategies to prevent and treat infections caused by 'Acinetobacter baumannii' and other antibiotic-resistant bacteria.

Multiple bacterial drug resistance (MDR) is a medical term that refers to the resistance of multiple strains of bacteria to several antibiotics or antimicrobial agents. This means that these bacteria have developed mechanisms that enable them to survive and multiply despite being exposed to drugs that were previously effective in treating infections caused by them.

MDR is a significant public health concern because it limits the treatment options available for bacterial infections, making them more difficult and expensive to treat. In some cases, MDR bacteria may cause severe or life-threatening infections that are resistant to all available antibiotics, leaving doctors with few or no effective therapeutic options.

MDR can arise due to various mechanisms, including the production of enzymes that inactivate antibiotics, changes in bacterial cell membrane permeability that prevent antibiotics from entering the bacteria, and the development of efflux pumps that expel antibiotics out of the bacteria. The misuse or overuse of antibiotics is a significant contributor to the emergence and spread of MDR bacteria.

Preventing and controlling the spread of MDR bacteria requires a multifaceted approach, including the judicious use of antibiotics, infection control measures, surveillance, and research into new antimicrobial agents.

'Acinetobacter calcoaceticus' is a species of gram-negative, aerobic bacteria that is commonly found in the environment, such as in soil and water. It is a non-motile, oxidase-negative organism that can form biofilms and has the ability to survive in a wide range of temperatures and pH levels.

While 'Acinetobacter calcoaceticus' itself is generally considered to be a low-virulence bacterium, it is closely related to other species within the genus 'Acinetobacter' that are known to cause healthcare-associated infections, particularly in immunocompromised patients or those with underlying medical conditions. These infections can include pneumonia, bloodstream infections, meningitis, and wound infections.

It is important to note that the identification of 'Acinetobacter calcoaceticus' can be challenging due to its tendency to form mixed cultures with other 'Acinetobacter' species, as well as its ability to undergo genetic changes that can make it difficult to distinguish from other members of the genus. Accurate identification and antimicrobial susceptibility testing are critical for appropriate treatment and infection control measures.

Anti-bacterial agents, also known as antibiotics, are a type of medication used to treat infections caused by bacteria. These agents work by either killing the bacteria or inhibiting their growth and reproduction. There are several different classes of anti-bacterial agents, including penicillins, cephalosporins, fluoroquinolones, macrolides, and tetracyclines, among others. Each class of antibiotic has a specific mechanism of action and is used to treat certain types of bacterial infections. It's important to note that anti-bacterial agents are not effective against viral infections, such as the common cold or flu. Misuse and overuse of antibiotics can lead to antibiotic resistance, which is a significant global health concern.

Cross infection, also known as cross-contamination, is the transmission of infectious agents or diseases between patients in a healthcare setting. This can occur through various means such as contaminated equipment, surfaces, hands of healthcare workers, or the air. It is an important concern in medical settings and measures are taken to prevent its occurrence, including proper hand hygiene, use of personal protective equipment (PPE), environmental cleaning and disinfection, and safe injection practices.

Carbapenems are a class of broad-spectrum beta-lactam antibiotics, which are used to treat severe infections caused by bacteria that are resistant to other antibiotics. They have a similar chemical structure to penicillins and cephalosporins but are more resistant to the enzymes produced by bacteria that can inactivate these other antibiotics. Carbapenems are often reserved for use in serious infections caused by multidrug-resistant organisms, and they are typically given intravenously in a hospital setting. Examples of carbapenems include imipenem, meropenem, doripenem, and ertapenem.

Colistin is an antibiotic that belongs to a class of drugs called polymyxins. It is primarily used to treat infections caused by Gram-negative bacteria, including some that are resistant to other antibiotics. Colistin works by disrupting the bacterial cell membrane and causing the bacterium to lose essential components, leading to its death.

Colistin can be administered intravenously or inhaled, depending on the type of infection being treated. It is important to note that colistin has a narrow therapeutic index, meaning that there is a small difference between the effective dose and the toxic dose. Therefore, it must be used with caution and under the close supervision of a healthcare professional.

Common side effects of colistin include kidney damage, nerve damage, and muscle weakness. It may also cause allergic reactions in some people. Colistin should not be used during pregnancy or breastfeeding unless the benefits outweigh the risks.

Microbial sensitivity tests, also known as antibiotic susceptibility tests (ASTs) or bacterial susceptibility tests, are laboratory procedures used to determine the effectiveness of various antimicrobial agents against specific microorganisms isolated from a patient's infection. These tests help healthcare providers identify which antibiotics will be most effective in treating an infection and which ones should be avoided due to resistance. The results of these tests can guide appropriate antibiotic therapy, minimize the potential for antibiotic resistance, improve clinical outcomes, and reduce unnecessary side effects or toxicity from ineffective antimicrobials.

There are several methods for performing microbial sensitivity tests, including:

1. Disk diffusion method (Kirby-Bauer test): A standardized paper disk containing a predetermined amount of an antibiotic is placed on an agar plate that has been inoculated with the isolated microorganism. After incubation, the zone of inhibition around the disk is measured to determine the susceptibility or resistance of the organism to that particular antibiotic.
2. Broth dilution method: A series of tubes or wells containing decreasing concentrations of an antimicrobial agent are inoculated with a standardized microbial suspension. After incubation, the minimum inhibitory concentration (MIC) is determined by observing the lowest concentration of the antibiotic that prevents visible growth of the organism.
3. Automated systems: These use sophisticated technology to perform both disk diffusion and broth dilution methods automatically, providing rapid and accurate results for a wide range of microorganisms and antimicrobial agents.

The interpretation of microbial sensitivity test results should be done cautiously, considering factors such as the site of infection, pharmacokinetics and pharmacodynamics of the antibiotic, potential toxicity, and local resistance patterns. Regular monitoring of susceptibility patterns and ongoing antimicrobial stewardship programs are essential to ensure optimal use of these tests and to minimize the development of antibiotic resistance.

Beta-lactamases are enzymes produced by certain bacteria that can break down and inactivate beta-lactam antibiotics, such as penicillins, cephalosporins, and carbapenems. This enzymatic activity makes the bacteria resistant to these antibiotics, limiting their effectiveness in treating infections caused by these organisms.

Beta-lactamases work by hydrolyzing the beta-lactam ring, a structural component of these antibiotics that is essential for their antimicrobial activity. By breaking down this ring, the enzyme renders the antibiotic ineffective against the bacterium, allowing it to continue growing and potentially causing harm.

There are different classes of beta-lactamases (e.g., Ambler Class A, B, C, and D), each with distinct characteristics and mechanisms for breaking down various beta-lactam antibiotics. The emergence and spread of bacteria producing these enzymes have contributed to the growing problem of antibiotic resistance, making it increasingly challenging to treat infections caused by these organisms.

To overcome this issue, researchers have developed beta-lactamase inhibitors, which are drugs that can bind to and inhibit the activity of these enzymes, thus restoring the effectiveness of certain beta-lactam antibiotics. Examples of such combinations include amoxicillin/clavulanate (Augmentin) and piperacillin/tazobactam (Zosyn).

Imipenem is an antibiotic medication that belongs to the class of carbapenems. It is used to treat various types of bacterial infections, including pneumonia, sepsis, and skin infections. Imipenem works by inhibiting the synthesis of bacterial cell walls, leading to bacterial death.

Imipenem is often combined with another medication called cilastatin, which helps to prevent the breakdown of imipenem in the body and increase its effectiveness. The combination of imipenem and cilastatin is available under the brand name Primaxin.

Like other antibiotics, imipenem should be used with caution and only when necessary, as overuse can lead to antibiotic resistance. It is important to follow the prescribing physician's instructions carefully and complete the full course of treatment, even if symptoms improve before the medication is finished.

Bacterial DNA refers to the genetic material found in bacteria. It is composed of a double-stranded helix containing four nucleotide bases - adenine (A), thymine (T), guanine (G), and cytosine (C) - that are linked together by phosphodiester bonds. The sequence of these bases in the DNA molecule carries the genetic information necessary for the growth, development, and reproduction of bacteria.

Bacterial DNA is circular in most bacterial species, although some have linear chromosomes. In addition to the main chromosome, many bacteria also contain small circular pieces of DNA called plasmids that can carry additional genes and provide resistance to antibiotics or other environmental stressors.

Unlike eukaryotic cells, which have their DNA enclosed within a nucleus, bacterial DNA is present in the cytoplasm of the cell, where it is in direct contact with the cell's metabolic machinery. This allows for rapid gene expression and regulation in response to changing environmental conditions.

Beta-lactam resistance is a type of antibiotic resistance in which bacteria have developed the ability to inactivate or circumvent the action of beta-lactam antibiotics. Beta-lactams are a class of antibiotics that include penicillins, cephalosporins, carbapenems, and monobactams. They work by binding to and inhibiting the activity of enzymes called penicillin-binding proteins (PBPs), which are essential for bacterial cell wall synthesis.

Bacteria can develop beta-lactam resistance through several mechanisms:

1. Production of beta-lactamases: These are enzymes that bacteria produce to break down and inactivate beta-lactam antibiotics. Some bacteria have acquired genes that encode for beta-lactamases that can hydrolyze and destroy the beta-lactam ring, rendering the antibiotic ineffective.
2. Alteration of PBPs: Bacteria can also develop mutations in their PBPs that make them less susceptible to beta-lactams. These alterations can reduce the affinity of PBPs for beta-lactams or change their conformation, preventing the antibiotic from binding effectively.
3. Efflux pumps: Bacteria can also develop efflux pumps that actively pump beta-lactam antibiotics out of the cell, reducing their intracellular concentration and limiting their effectiveness.
4. Biofilm formation: Some bacteria can form biofilms, which are communities of microorganisms that adhere to surfaces and are encased in a protective matrix. Biofilms can make bacteria more resistant to beta-lactams by preventing the antibiotics from reaching their targets.

Beta-lactam resistance is a significant public health concern because it limits the effectiveness of these important antibiotics. The overuse and misuse of beta-lactams have contributed to the emergence and spread of resistant bacteria, making it essential to use these antibiotics judiciously and develop new strategies to combat bacterial resistance.

Bacterial drug resistance is a type of antimicrobial resistance that occurs when bacteria evolve the ability to survive and reproduce in the presence of drugs (such as antibiotics) that would normally kill them or inhibit their growth. This can happen due to various mechanisms, including genetic mutations or the acquisition of resistance genes from other bacteria.

As a result, bacterial infections may become more difficult to treat, requiring higher doses of medication, alternative drugs, or longer treatment courses. In some cases, drug-resistant infections can lead to serious health complications, increased healthcare costs, and higher mortality rates.

Examples of bacterial drug resistance include methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE), and multidrug-resistant tuberculosis (MDR-TB). Preventing the spread of bacterial drug resistance is crucial for maintaining effective treatments for infectious diseases.

An encyclopedia is a comprehensive reference work containing articles on various topics, usually arranged in alphabetical order. In the context of medicine, a medical encyclopedia is a collection of articles that provide information about a wide range of medical topics, including diseases and conditions, treatments, tests, procedures, and anatomy and physiology. Medical encyclopedias may be published in print or electronic formats and are often used as a starting point for researching medical topics. They can provide reliable and accurate information on medical subjects, making them useful resources for healthcare professionals, students, and patients alike. Some well-known examples of medical encyclopedias include the Merck Manual and the Stedman's Medical Dictionary.

... species are a key source of infection in debilitated patients in the hospital, in particular the species ... Acinetobacter is frequently isolated in nosocomial infections, and is especially prevalent in intensive care units, where both ... Visca P, Seifert H, Towner KJ (December 2011). "Acinetobacter infection--an emerging threat to human health". IUBMB Life. 63 ( ... Trials to implement vaccines to prevent Acinetobacter infections were documented. Reports suggest this bacterium is susceptible ...
When infections are caused by antibiotic-susceptible Acinetobacter isolates, there may be several therapeutic options, ... 2012). "Increase of carbapenem-resistant Acinetobacter baumannii infection in acute care hospitals in Taiwan: Association with ... Aivazova, V; Kainer, F; Friese, K; Mylonas, I (January 2010). "Acinetobacter baumannii infection during pregnancy and ... Acinetobacter can be spread by person-to-person contact or contact with contaminated surfaces. Acinetobacter can enter through ...
Rathinavelu, S; Zavros, Y; Merchant, JL (June 2003). "Acinetobacter lwoffii infection and gastritis". Microbes and Infection / ... Acinetobacter lwoffii, formerly known as Mima polymorpha or Acinetobacter calcoaceticus var. lwoffii, is a non-fermentative ... In addition to that, it can cause infections in human hosts, particularly catheter-associated infections in immunocompromised ... Type strain of Acinetobacter lwoffii at BacDive - the Bacterial Diversity Metadatabase v t e (Articles with short description, ...
"Blood stream infections caused by Acinetobacter ursingii in an obstetrics ward". Infection, Genetics and Evolution. 11 (1): 52- ... "Acinetobacter ursingii sp. nov. and Acinetobacter schindleri sp. nov., isolated from human clinical specimens". International ... and antimicrobial susceptibilities of Acinetobacter ursingii and Acinetobacter schindleri, two frequently misidentified ... Acinetobacter ursingii is a species of potentially pathogenic bacteria. Its type strain is LUH 3792T (= NIPH 137T = LMG 19575T ...
... can cause bloodstream infection in neonates. LPSN lpsn.dsmz.de Straininfo of Acinetobacter soli Dongyou Liu ... "Acinetobacter soli as a Cause of Bloodstream Infection in a Neonatal Intensive Care Unit". Journal of Clinical Microbiology. 49 ... Kim, D.; Baik, K. S.; Kim, M. S.; Park, S. C.; Kim, S. S.; Rhee, M. S.; Kwak, Y. S.; Seong, C. N. (2008). "Acinetobacter soli ... Type strain of Acinetobacter soli at BacDive - the Bacterial Diversity Metadatabase v t e (Articles with short description, ...
"Clinical characteristics of patients with Acinetobacter junii infection". Journal of Microbiology, Immunology, and Infection = ... nov., Acinetobacter haemolyticus sp. nov., Acinetobacter johnsonii sp. nov., and Acinetobacter junii sp. nov. and Emended ... "Acinetobacter junii" at the Encyclopedia of Life Type strain of Acinetobacter junii at BacDive - the Bacterial Diversity ... Bouvet, P. J. M.; Grimont, P. A. D. (1986). "Taxonomy of the Genus Acinetobacter with the Recognition of Acinetobacter ...
LaVergne, Stephanie (March 2018). "Phage Therapy for a Multidrug-Resistant Acinetobacter baumannii Craniectomy Site Infection ... was suffering from a life-threatening multi-drug resistant Acinetobacter baumannii infection, that he had acquired while on ... He is an expert in HIV and hepatitis C (HCV) infection and treatment, and in 2016, was the first physician to treat a patient ... UC San Diego Health, Newsroom (April 2017). "Novel Phage Therapy Saves Patient with Multidrug-Resistant Bacterial Infection". ...
Use of colistin to treat Acinetobacter baumannii infections has led to the development of resistant bacterial strains. They ... October 2006). "Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii ... August 2005). "Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical ... Towner KJ (2008). "Molecular Basis of Antibiotic Resistance in Acinetobacter spp.". Acinetobacter Molecular Biology. Caister ...
"PheWAS uncovers a pathological role of coagulation Factor X during Acinetobacter baumannii infection". Infection and Immunity. ... Polymorphisms in Factor X have been associated with an increased prevalence in bacterial infections, suggesting a possible role ...
Infections caused by the non-fermenting gram-negative bacteria Pseudomonas aeruginosa and Acinetobacter baumanni are most ... Rice LB (2006). "Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter ... and meropenem are recommended for high-risk community-acquired abdominal infections and for abdominal infections that are ... "Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection ...
Iregbu, K. C.; Ogunsola, F. T.; Odugbemi, T. O. (2002). "Infections caused by Acinetobacter species and their susceptibility to ... She was a founding member of the Nigerian Society for Infection control in 1998 and is also a member of the Global Infection ... 1996 Infections caused by Acinetobacter species and their susceptibility to 14 antibiotics in Lagos University Teaching ... She has also been the chairman of the Infection Control Committee of Lagos University Teaching Hospital. Additionally, she is ...
... a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam". ... Restores Sulbactam Activity Against Acinetobacter Species". Clinical Infectious Diseases. 76 (Supplement_2): S194-S201. doi: ... beta-lactamase inhibitor used in combination with sulbactam to treat susceptible strains of bacteria in the genus Acinetobacter ...
... is a bacterium from the genus of Acinetobacter which has been isolated from human infections. ... Parte, A. C. "Acinetobacter". LPSN. Nemec, A.; Radolfova-Krizova, L.; Maixnerova, M.; Sedo, O. (July 2017). "Acinetobacter ... Type strain of Acinetobacter colistiniresistens at BacDive - the Bacterial Diversity Metadatabase v t e (Articles with short ... isolated from human infections and characterized by intrinsic resistance to polymyxins". International Journal of Systematic ...
April 2007). "Control of an outbreak of pandrug-resistant Acinetobacter baumannii colonization and infection in a neonatal ... In the US, the most frequent type of hospital infection is urinary tract infection (36%), followed by surgical site infection ( ... infections of surgery site (14.2%). Infections of the skin and mucous membrane (10.2%), other respiratory infections (6.8%) and ... Nosocomial infections can cause severe pneumonia and infections of the urinary tract, bloodstream and other parts of the body. ...
Acinetobacter is a gram-negative bacteria that causes pneumonia or bloodstream infections in critically ill patients. Multidrug ... Infections are most frequent in people who have had recent medical and/or antibiotic treatment. C. difficile infections ... Associated with these infections were an estimated 15,000 deaths. The CDC estimates that C. difficile infection costs could ... Centers for Disease Control Prevention (CDC). (2004). "Acinetobacter baumannii infections among patients at military medical ...
"Co-infection and ICU-acquired infection in COIVD-19 ICU patients: a secondary analysis of the UNITE-COVID data set". Critical ... It is often resistant to a wide array of antibiotics but is usually sensitive to co-trimoxazole Acinetobacter are becoming more ... Risk factors for infection with an MDR strain include ventilation for more than five days, recent hospitalization (last 90 days ... As a result of intubation many of the body's defenses against infections are reduced or impaired; this can result in an ability ...
Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection". ... Infection prevention is the most efficient strategy of prevention of an infection with a MDR organism within a hospital, ... Use the appropriate antimicrobial for an infection; e.g. no antibiotics for viral infections Identify the causative organism ... Lomentospora prolificans infections are often fatal because of their resistance to multiple antifungal agents. HIV is the prime ...
... -Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection". ... For instance, infection of Pseudomonas aeruginosa by the temperate phage PaP3 changed the expression of 38% (2160/5633) of its ... Therapeutic efficacy of a phage cocktail was evaluated in a mice model with nasal infection of multidrug-resistant (MDR) A. ... Maintaining an appropriate balance in the amounts of each of these proteins produced during viral infection appears to be ...
... critically ill with a completely antibiotic-resistant Acinetobacter baumannii infection following severe pancreatitis. Viruses ... Biofilm infections are very challenging to treat with antibiotics. The biofilm matrix and surrounding bacterial membranes can ... PhagoBurn, a phase-1 and 2 trial of phage therapy against P. aeruginosa wound infection in France and Belgium in 2015-17, was ... These factors make phage therapy an enticing option for the treatment of such infections, and there are currently two ways to ...
He is known for his research on healthcare related infections with special emphasis on Acinetobacter, Klebsiella, ESKAPE, Human ...
... therapy after he acquired a life-threatening infection with a 'superbug', Acinetobacter baumannii. Although phage therapy had ... Her early research in Vancouver, Canada identified a major outbreak of HIV infection that occurred among injection drug users ... As a result of the Patterson case, dozens other patients with multidrug resistant bacterial infections have been treated with ... Joel Grimwood was a patient who was ineligible for heart transplantation due to antimicrobial resistant infection. With phage ...
Patterson had a systemic Acinetobacter baumannii infection that manifested while he was on vacation with his wife, Steffanie ... The center currently treats patients with life-threatening multi-drug resistant infections with phage therapy, on a case-by- ... IPATH aims to initiate phase I/II phage therapy clinical trials, focusing on patients with cystic fibrosis and infections ... Phage therapy is the method by which bacteriophages (viruses which infect bacteria) are used to treat bacterial infections or ...
... associated with hospital-acquired infections include Acinetobacter baumannii, which cause bacteremia, ... It has also been studied in gram-negative species found in soil such as Pseudomonas stutzeri, Acinetobacter baylyi, and gram- ... That is why some infections with gram-negative bacteria can lead to life-threatening septic shock. The outer membrane protects ... Drugs commonly used to treat gram negative infections include amino, carboxy and ureido penicillins (ampicillin, amoxicillin, ...
Cutaneous infections caused by Acinetobacter species (implicated in a number of hospital-acquired infections such as bacteremia ... Woolever, Donald Raj (February 7, 2020). "Skin Infections and Outpatient Burn Management: Fungal and Viral Skin Infections". FP ... Group B streptococcal infection, also known as Group B streptococcal disease or just Group B strep, is the infection caused by ... Common viral skin infections include herpes simplex virus infection, herpes zoster, cutaneous and genital warts, and molluscum ...
... research into pathogens infecting combat wounds resulting in the first descriptions of acinetobacter baumannii infection in ... reflecting its focus on tropical infections of interest to the military such as malaria and Dengue fever. In 1947 NAMRU-2 ...
... airborne acinetobacter infections in a ward were eliminated by the installation of a negative air ioniser-the infection rate ... The frequency of nosocomial infections in British hospitals prompted the National Health Service (NHS) to research the ... McDowell, Natasha (3 January 2003). "Air ionisers wipe out hospital infections". The New Scientist. No. Daily news. Retrieved ...
Acinetobacter infections, a frequent cause of hospital-acquired pneumonia and life-threatening blood or wound infections. ... He has been the editor-in-chief of Infection and Immunity for 10 years and Section Editor of J. of Immunology for 5 years. He ... He later served as the editor-in-chief of scientific journal, Infection and Immunity for 10 years and section editor of the ... He has since accumulated 'near 40 patents' most dealing with methods to prevent bacterial infections. One such patent dealing ...
... complicated intra-abdominal infections, complicated urinary tract infections, and nosocomial respiratory tract infections. ... Acinetobacter, and Enterobacter. In addition, some Mycobacteria, including the bacteria that cause tuberculosis, are ... Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, but other types of antibiotics are more ... In the past, the aminoglycosides have been used in conjunction with beta-lactam antibiotics in streptococcal infections for ...
... is also being investigated for the treatment of infections caused by the Gram-negative bacillus Acinetobacter ... Rifabutin is also used in the treatment of Mycobacterium avium complex disease, a bacterial infection most commonly encountered ... Rifamycins, including rifabutin, are useful in the treatment of Chlamydophila pneumoniae (Cpn) infection.[citation needed] ... September 2020). "A nutrient-limited screen unmasks rifabutin hyperactivity for extensively drug-resistant Acinetobacter ...
They can cause infection in debilitated patients. LPSN lpsn.dsmz.de "Straininfo of Acinetobacter pittii". Archived from the ... formerly Acinetobacter genomic species 3) and Acinetobacter nosocomialis sp. nov. (formerly Acinetobacter genomic species 13TU ... "Acinetobacter pittii and Acinetobacter nosocomialis among clinical isolates of the Acinetobacter calcoaceticus-baumannii ... characterization of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex with the proposal of Acinetobacter pittii ...
... secondary infection was defined as infection with a different organism at the same site as the initial Acinetobacter infection. ... had any Acinetobacter infection. The incidence of Acinetobacter infection during the study period represents a significant ... only 2 active-duty soldiers had Acinetobacter infection. A soft tissue infection with Acinetobacter developed in 1 soldier with ... Most Acinetobacter infections reported in the literature reflect nosocomial Acinetobacter, as hospitalized patients are at ...
Acinetobacter Infections - Etiology, pathophysiology, symptoms, signs, diagnosis & prognosis from the MSD Manuals - Medical ... multidrug resistant-see table Risk Factors for Acinetobacter Infection Risk Factors for Acinetobacter Infection ). ... Acinetobacter species can also cause wound infections and suppurative infections (eg, abscesses) in any organ system, including ... The most common site for infection is the respiratory system, but Acinetobacter species can also cause suppurative infections ...
Acinetobacter baumannii is a pleomorphic aerobic gram-negative bacillus (similar in appearance to Haemophilus influenzae on ... The most common infection-causing species is A baumannii, followed by Acinetobactercalcoaceticus and Acinetobacterlwoffii. [1] ... When Acinetobacter infections occur, they usually involve organ systems that have a high fluid content (eg, respiratory tract, ... When Acinetobacter causes actual infection, the pathological changes that occur depend on the organ system involved. The ...
infection control, guidelines, recommendations, mdro, mrsa, vre, visa, vrsa, esbl ... and Acinetobacter, see the Healthcare-Associated Infection (HAI) website. ... V.A.5. Infection Control Precautions to Prevent Transmission of MDROs. Recommendations for infection control precautions for ... Include information on changes in prevalence or incidence of infection, results of assessments for system failures, and action ...
... except one patient who died before a diagnosis of acinetobacter infection was confirmed. Multi-resistant Acinetobacter spp. ... Four of the infected patients died directly or indirectly from infection with multi-resistant Acinetobacter spp., either while ... The mean interval from admission to the first isolation of a multi-resistant Acinetobacter strain was 6.7 and 12.1 days in the ... Multi-resistant Acinetobacter strains were isolated most frequently from the respiratory tract, and eight patients had probable ...
Acinetobacter baumannii infection presents a high mortality rate and few therapeutic options. This study aimed to evaluate ... infections treated with oral doxycycline. A retrospective cohort of hospitalized patients with confirmed Acinetobacter spp. ... Oral doxycycline to carbapenem-resistant Acinetobacter baumannii infection as a polymyxin- Oral doxycycline to carbapenem- ... Infecções por Acinetobacter; Acinetobacter baumannii; Humanos; Pessoa de Meia-Idade; Doxiciclina/farmacologia; Doxiciclina/uso ...
... our team research the Europe Acinetobacter Infections Treatment market by type, application, region and manufacturer 2014-2019 ... 6.2.3 UK Acinetobacter Infections Treatment Price (USD/Unit) of Manufacturers 2014-2019. 6.2.4 UK Acinetobacter Infections ... 6.8.1 Acinetobacter Infections Treatment Sales (K Units) and Share of Manufacturers 2014-2019. 6.8.2 Acinetobacter Infections ... Figure UK Acinetobacter Infections Treatment Gross Margin of Manufacturers in 2014_x000D_. Figure UK Acinetobacter Infections ...
Categories: Acinetobacter Infections Image Types: Photo, Illustrations, Video, Color, Black&White, PublicDomain, ...
Rifampicin and colistin association in the treatment of severe multiresistant Acinetobacter baumannii infections. *B Charra1, ... The increased incidence of nosocomial infections by multidrug-resistant Acinetobacter baumannii creates demand on the ... Rifampicin and colistin association in the treatment of severe multiresistant Acinetobacter baumannii infections ... Rifampicin and colistin association in the treatment of severe multiresistant Acinetobacter baumannii infections. Crit Care 12 ...
Acinetobacter infection. New England Journal of Medicine, 2008, 358:1271-1281.. *Johnson JR et al. Similarity between human and ... وانخفضت حساسية الراكدة Acinetobacter للإيميبينيم من 99.0% في عام 2004 إلى 32.5% فقط في عام 2008. وظهرت في نفس الفترة مقاومة ... Sensitivity of Acinetobacter spp. to imipenem dropped from 99.0% in 2004 to only 32.5% in 2008. During the same period, almost ... Journal of Infection in Developing Countries, 2009, 3(7):491-497.. *Shibl A. The problem of antibiotic resistance. Arab Health ...
Acinetobacter species are a key source of infection in debilitated patients in the hospital, in particular the species ... Acinetobacter is frequently isolated in nosocomial infections, and is especially prevalent in intensive care units, where both ... Visca P, Seifert H, Towner KJ (December 2011). "Acinetobacter infection--an emerging threat to human health". IUBMB Life. 63 ( ... Trials to implement vaccines to prevent Acinetobacter infections were documented. Reports suggest this bacterium is susceptible ...
... is defined as a lung infection that begins in a nonintubated patient within 48 hours of admission. Ventilator-associated ... trial showed sulbactam/durlobactam was noninferior to colistin in patients with carbapenem-resistant Acinetobacter infections. ... Acinetobacter species commonly colonize respiratory tract secretions in patients in the ICU. HAP caused by Acinetobacter ... 28- Infections in Critically Ill Patients. Hupp JR, Ferneini EM. Head, Neck, and Orofacial Infections. Elsevier; 2016. 383-394 ...
MALDI-TOF MS for identification of community-acquired Acinetobacter baumannii complex infections. In: Pathology. 2016 ; Vol. 48 ... MALDI-TOF MS for identification of community-acquired Acinetobacter baumannii complex infections. Pathology. 2016;48(1):100-103 ... MALDI-TOF MS for identification of community-acquired Acinetobacter baumannii complex infections. / McAuliffe, GN; Baird, ... title = "MALDI-TOF MS for identification of community-acquired Acinetobacter baumannii complex infections", ...
MDR Acinetobacter infection compared with patients with susceptible Acinetobacter infections and patients without Acinetobacter ... MDR Acinetobacter infection compared with patients with susceptible Acinetobacter infections and patients without Acinetobacter ... MDR Acinetobacter infection compared with patients with susceptible Acinetobacter infections and patients without Acinetobacter ... MDR Acinetobacter infection compared with patients with susceptible Acinetobacter infections and patients without Acinetobacter ...
... report delivers an in-depth understanding of the disease ... Acinetobacter Infection - Epidemiology Forecast - 2032. January, 2022 , Published by: DelveInsight , USD $3,950 ... 2. Executive Summary of Clostridium Difficile Infections. 3. Clostridium Difficile Infections: Disease Background and Overview ... Clostridium Difficile Infections Treatment and Management. 6.2. Clostridium Difficile Infections Treatment Algorithm. 7. KOL ...
Case Report: Molecular Characterization of Bloodstream Infections due to Carbapenem-Resistant Acinetobacter baumannii: A ... Case Report: Giant Oral Ulcers Attributed to Cytomegalovirus Infection in a Patient with AIDS ...
The purpose of this review was to draw attention to the potential risk of MDR Acinetobacter infections in Türkiye. ... Resistance to colistin, which was frequently used in the treatment of Acinetobacter baumannii infections in previous years, has ... The use of fosfomycin in the treatment of carbapenem-resistant Acinetobacter infections. D J Med Sci 2022;8(2):90-95. ... The use of fosfomycin in the treatment of carbapenem-resistant Acinetobacter infections. ...
Outbreak of Acinetobacter baumannii Bacteremia Related to Contaminated Morphine Used for Patient-Controlled Analgesia - Volume ... Infection Control & Hospital Epidemiology , Volume 28 , Issue 10 , October 2007 , pp. 1213 - 1217 ... Postoperative infections traced to contamination of an intravenous anesthetic, propofol. N Engl J Med 1995;333:147-154.Google ... Outbreak of Acinetobacter baumannii Bacteremia Related to Contaminated Morphine Used for Patient-Controlled Analgesia. ...
... monotherapy versus non-COL based combinations in the treatment of bloodstream infections (BSIs) due to multidrug resistant ... Comparison of colistin monotherapy and non-colistin combinations in the treatment of multi-drug resistant Acinetobacter spp. ... Acinetobacter spp.(MDR-A) . Materials and Methods: Retrospective data of 107 MDR-A BSI cases from 27 tertiary centers in Turkey ...
Characterized Acinetobacter baumannii-calcoaceticus complex and Pseudomonas aeruginosa Clinical Isolates Causing Infection in ... Characterized Acinetobacter baumannii-calcoaceticus complex and Pseudomonas aeruginosa Clinical Isolates Causing Infection in ...
... correlates of fibrinogen binding by Acinetobacter adhesins critical in catheter-associated urinary tract infections. Together ... correlates of fibrinogen binding by Acinetobacter adhesins critical in catheter-associated urinary tract infections. ...
GENETIC VARIANTS OF RESISTANCE DETERMINANT TO SILVER IN EPIDEMIC STRAINS OF ACINETOBACTER BAUMANNII ... Keywords COVID-19 HIV infection Helicobacter pylori Mycobacterium tuberculosis PCR SARS-CoV-2 antibodies children cytokines ... Keywords COVID-19 HIV infection Helicobacter pylori Mycobacterium tuberculosis PCR SARS-CoV-2 antibodies children cytokines ... GENETIC VARIANTS OF RESISTANCE DETERMINANT TO SILVER IN EPIDEMIC STRAINS OF ACINETOBACTER BAUMANNII - PDF (English). Download ...
Antibiotic Treatment of Acinetobacter baumannii Superinfection in Patients With SARS-CoV-2 Infection Admitted to Intensive Care ... Antibiotic Treatment of Acinetobacter baumannii Superinfection in Patients With SARS-CoV-2 Infection Admitted to Intensive Care ... to our ICU from March 2020 to May 2021 for acute respiratory failure from SARS-CoV-2 infection who developed PDR Acinetobacter ... to our ICU from March 2020 to May 2021 for acute respiratory failure from SARS-CoV-2 infection who developed PDR Acinetobacter ...
They have been used in an effort to combat hospital-acquired infections due to bacteria such as Clostridium difficile, ... Acinetobacter spp., Vancomycin-resistant enterococcus, and methicillin-resistant Staphylococcus aureus, as well as fungi and ... As technology advances to improve health care and reduce hospital-acquired infections, more such hazards may emerge. This case ... Infection-control; Disease-control; Environmental-control-equipment; Control-equipment; Controlled-environment; Environmental- ...
Acinetobacter baumannii. Acinetobacter Infections. Staphylococcal Infections. Staphylococcus aureus. Bacteremia. Gram-Positive ...
There are reports of infection by Acinetobacter spp. associated with mycobacteriosis in falcons (Muller et al., 2010MULLER, M.G ... Carbapenem-resistant Acinetobacter baumannii ST294 harbouring the OXA-72 carbapenemase from a captive grey parrot. The Journal ... Nosocomial Acinetobacter pneumonia: treatment and prognostic factors in 356 cases. Respirology (Carlton, Vic.), vol. 21, no. 2 ... Acinetobacter baumammii in Localised Cutaneous Mycobacteriosis in Falcons. Veterinary Medicine International, vol. 2010, pp. 1- ...
1. Acinetobacter baumannii (carbapenem): Hospital infections. 2. Pseudomonas aeruginosa (carbapenem): Hospital infections. 3. ... 4. Enterococcus faecium (vancomycin): Hospital infections. 5. Staphylococcus aureus (methicillin, vancomycin): Skin infections ... pneumonia, bloodstream infections. 6. Helicobacter pylori (clarithromycin): Infection can lead to stomach ulcers and cancer. 7 ... "And if you have a new antibiotic, you do really want to hold it in reserve for those resistant infections." That means the ...
  • Community-acquired infections (mostly pneumonia) are more common in tropical climates. (msdmanuals.com)
  • These infections may occur as outbreaks rather than isolated cases of nosocomial pneumonia. (medscape.com)
  • The 2005 IDSA guidelines for hospital-acquired pneumonia discuss the role of Acinetobacter as a cause of nosocomial pneumonia. (medscape.com)
  • Multi-resistant Acinetobacter strains were isolated most frequently from the respiratory tract, and eight patients had probable or suspected pneumonia caused by a multi-resistant Acinetobacter sp. (microbiologyresearch.org)
  • Hospital-acquired pneumonia (HAP), or nosocomial pneumonia, is a lower respiratory infection that was not incubating at the time of hospital admission and that presents clinically 2 or more days after hospitalization. (medscape.com)
  • Acinetobacter bacteria causes pneumonia and wound, bloodstream, and urinary tract infections. (cdc.gov)
  • The new guidelines are designed to reduce the incidence of pneumonia and other severe, acute lower respira- tory tract infections in acute-care hospitals and in other health-care settings (e.g., ambulatory and long-term care institu- tions) and other facilities where health care is provided. (cdc.gov)
  • ATTACK is our single Phase 3 registrational trial that will evaluate SUL-DUR in patients with confirmed carbapenem-resistant Acinetobacter pneumonia and/or bloodstream infections. (biospace.com)
  • This report is the case of an immunosuppressed transplant patient with a fatal pneumonia due to pan-resistant Acinetobacter baumannii. (usp.br)
  • Oral doxycycline to carbapenem-resistant Acinetobacter baumannii infection as a polymyxin-sparing strategy: results from a retrospective cohort. (bvsalud.org)
  • The list ranks 12 bacteria or bacterial families and is topped by carbapenem-resistant Acinetobacter baumannii . (bioedonline.org)
  • Carbapenem-resistant Acinetobacter baumannii (CRAB) presents a serious therapeutic and infection control challenge. (frontiersin.org)
  • This guideline focuses on carbapenem-resistant Enterobacteriales (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB), and carbapenem-resistant Pseudomonas aeruginosa (CRPA). (bvsalud.org)
  • These bacteriophages appear to be most similar to bacteriophages that infect Pseudomonas and Ralstonia rather than Enterobacteriales bacteria by protein similarity, however, we were only able to detect infection of Erwinia and the closely related strains of Pantoea . (frontiersin.org)
  • Infections caused by Pseudomonas aeruginosa or Acinetobacter baumannii are of greatest concern for hospitalized patients, particularly those in intensive care units (ICUs). (magiran.com)
  • Maxipime treats several types bacterial infections. (rxwiki.com)
  • Maxipime is a prescription medication used to treat bacterial infections of the lungs, skin, abdomen, and urinary tract. (rxwiki.com)
  • Felix d'Herelle first coined the term "bacteriophage" ( 4 ), literally meaning "bacterium eater," and began using phages to treat bacterial infections in human patients ( Fig. 1 ). (asm.org)
  • Commonly, this stems from unclear instructions on self-administration of antibiotics, use of sub-antimicrobial dosing, prescription of antibiotics for minor bacterial infections, use of antibacterial drugs for non-bacterial infections, and use of broad-spectrum antibiotics for narrow-spectrum indications. (skintherapyletter.com)
  • Diagnosis of infection was based on clinical data and isolation of bacteria. (biomedcentral.com)
  • Acinetobacter is a genus of Gram-negative bacteria belonging to the wider class of Gammaproteobacteria. (wikipedia.org)
  • citation needed] Bacteria of the genus Acinetobacter are known to form intracellular inclusions of polyhydroxyalkanoates under certain environmental conditions (e.g. lack of elements such as phosphorus, nitrogen, or oxygen combined with an excessive supply of carbon sources). (wikipedia.org)
  • They have been used in an effort to combat hospital-acquired infections due to bacteria such as Clostridium difficile, Acinetobacter spp. (cdc.gov)
  • The genus Acinetobacter comprises a complex group of Gram-negative bacteria. (nature.com)
  • CDC's Antibiotic Resistance Threats in the United States, 2019 [PDF - 150 pages] (2019 AR Threats Report) includes the latest national death and infection estimates for 18 antimicrobial-resistant bacteria and fungi. (cdc.gov)
  • Researchers studying hand contamination and Acinetobacter, a bacteria that can cause healthcare-associated infections, found that healthcare personnel were likely to have the bacteria on their hands after activities as brief as touching a bed rail. (cdc.gov)
  • Bacteria aren't visible, but busy healthcare providers might forget that clean-looking hands can be contaminated with germs that can cause infections. (cdc.gov)
  • To reduce the development of drug-resistant bacteria and maintain the effectiveness of TYGACIL and other antibacterial drugs, TYGACIL should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. (druglib.com)
  • BACKGROUND: Tigecycline, a first-in-class broad-spectrum glycylcycline antibiotic, has broad-spectrum in vitro activity against bacteria commonly encountered in complicated intra-abdominal infections (cIAIs), including aerobic and facultative Gram-positive and Gram-negative bacteria and anaerobic bacteria. (druglib.com)
  • Therefore, effective strategies must be implemented to combat antibiotic-resistant bacteria, along with stricter adherence to infection control programmes. (who.int)
  • We also hear a lot about this newest bacteria, multi-drug resistant Acinetobacter, and we're very concerned about the problems with it. (cdc.gov)
  • Noble W. C Hospital epidemiology of Acinetobacter infection. (microbiologyresearch.org)
  • Joly-Guillou M. L. , Bergogne-Bérézin E. , Vieu J. F. Epidemiology of Acinetobacter and its resistance to antibiotics in hospitals a 5-year evaluation. (microbiologyresearch.org)
  • DelveInsight's "" Clostridium Difficile Infections - Epidemiology Forecast to 2032 "" report delivers an in-depth understanding of the disease, historical and forecasted Clostridium Difficile Infections epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. (marketresearch.com)
  • The DelveInsight Clostridium Difficile Infections epidemiology report gives a thorough understanding of the Clostridium Difficile Infections by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. (marketresearch.com)
  • The report covers the detailed information of the Clostridium Difficile Infections epidemiology scenario in seven major countries (US, EU5, and Japan). (marketresearch.com)
  • The Clostridium Difficile Infections epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. (marketresearch.com)
  • The Clostridium Difficile Infections epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. (marketresearch.com)
  • The Clostridium Difficile Infections epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. (marketresearch.com)
  • The Clostridium Difficile Infections epidemiology covered in the report provides historical as well as forecasted Clostridium Difficile Infections epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032. (marketresearch.com)
  • The DelveInsight Clostridium Difficile Infections report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. (marketresearch.com)
  • What are the key findings pertaining to the Clostridium Difficile Infections epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)? (marketresearch.com)
  • Genomic epidemiology of severe community-onset Acinetobacter baumannii infection. (cdc.gov)
  • At the conclusion of today's session the participant will be able to explain the epidemiology of C. auris , describe the guidance for diagnosis and treatment of C. auris , and describe the infection control recommendations for containing C. auris . (cdc.gov)
  • Two hundred twenty-one isolates of Acinetobacter baumannii and 15 of Acinetobacter genospecies 3 (AG3) were consecutively collected in a 30-day period during the nationwide project GEIH-Ab2000. (us.es)
  • When Acinetobacter infections occur, they usually involve organ systems that have a high fluid content (eg, respiratory tract, CSF, peritoneal fluid, urinary tract). (medscape.com)
  • Similarly, Acinetobacter urinary tract infections are clinically indistinguishable from catheter-associated bacteremias caused by other aerobic gram-negative bacilli. (medscape.com)
  • Acinetobacter colonization is particularly common in patients who are intubated and in those who have multiple intravenous lines or monitoring devices, surgical drains, or indwelling urinary catheters. (medscape.com)
  • Ventilator-associated events (39.5%), urinary tract infections (22.7%), and bloodstream infections (14.8%) were the main types of infection. (who.int)
  • Resistance to colistin, which was frequently used in the treatment of Acinetobacter baumannii infections in previous years, has pushed the use of fosfomycin to the forefront of research. (journalmeddbu.com)
  • Outbreak of Acinetobacter baumannii Bacteremia Related. (cambridge.org)
  • In the hospital setting, Acinetobacter species are an important cause of nosocomial infection, yet these infections were rarely encountered in our facility until we began observing them in soldiers with infected wounds. (cdc.gov)
  • War wound infection and osteomyelitis caused by multidrug-resistant (MDR) Acinetobacter species have been prevalent during the 2003-2005 military operations in Iraq. (cdc.gov)
  • This relative increase of wounded casualties has led to an increased incidence of war wound infection and osteomyelitis, especially caused by multidrug-resistant (MDR) Acinetobacter species. (cdc.gov)
  • Also, the number of multidrug-resistant AB infections has increased in service members who were injured and treated in Iraq, Kuwait, and Afghanistan. (msdmanuals.com)
  • for all healthcare settings independent of the prevalence of multidrug resistant organism (MDRO) infections or the population served. (cdc.gov)
  • The increased incidence of nosocomial infections by multidrug-resistant Acinetobacter baumannii creates demand on the application of some combinations of older antimicrobials on that species. (biomedcentral.com)
  • The effect of multidrug-resistant (MDR) Acinetobacter infection on clinical outcomes has not been reported. (elsevierpure.com)
  • Objectives: To compare the efficacy of colistin (COL) monotherapy versus non-COL based combinations in the treatment of bloodstream infections (BSIs) due to multidrug resistant Acinetobacter spp. (sdu.edu.tr)
  • Through the dedication of our employees and partners, we have maintained momentum in our Phase 3 registrational trials addressing multidrug-resistant Acinetobacter infections and uncomplicated gonorrhea," commented Manos Perros, President and Chief Executive Officer of Entasis Therapeutics. (biospace.com)
  • We are especially encouraged by the progress achieved in ATTACK, our Phase 3 trial for multidrug-resistant Acinetobacter infections where we now have a clear line of sight to enrolling 120 evaluable patients with carbapenem-resistant infections. (biospace.com)
  • The trial, designed to assess the safety and efficacy of oral zoliflodacin versus the current standard of care combination of intramuscular ceftriaxone plus oral azithromycin, is actively enrolling patients with uncomplicated gonorrhea, including infections potentially caused by multidrug-resistant strains of N. gonorrhoeae . (biospace.com)
  • While multidrug-resistant infections are clearly on the rise, the cause remains unclear. (medscape.com)
  • Sporadic examples of infection with multi-resistant Acinetobacter spp. (microbiologyresearch.org)
  • In the most recent outbreak, 11 patients were infected with multi-resistant Acinetobacter strains and 26 patients were colonised. (microbiologyresearch.org)
  • Four of the infected patients died directly or indirectly from infection with multi-resistant Acinetobacter spp. (microbiologyresearch.org)
  • The mean interval from admission to the first isolation of a multi-resistant Acinetobacter strain was 6.7 and 12.1 days in the infected and colonised groups, respectively. (microbiologyresearch.org)
  • Multi-resistant Acinetobacter spp. (microbiologyresearch.org)
  • Patients were followed up to 23 months after completing therapy, and none had recurrent infection with Acinetobacter species. (cdc.gov)
  • In nonconflict environments, Acinetobacter species are rarely responsible for community-acquired infections. (cdc.gov)
  • This case series reviews 1 military medical center's experience with these infections, including species identified, antimicrobial drug-susceptibility patterns, antimicrobial drug therapy, and clinical outcomes. (cdc.gov)
  • The Acinetobacter has more than 50 species, most of which are nonpathogenic environmental organisms. (medscape.com)
  • The most common infection-causing species is A baumannii, followed by Acinetobacter calcoaceticus and Acinetobacter lwoffii . (medscape.com)
  • Acinetobacter species can be transmitted to patients because of their persistence on environmental surfaces and because of colonization of the hands of healthcare workers. (medscape.com)
  • Acinetobacter species are oxidase-negative, exhibit twitching motility, and occur in pairs under magnification. (wikipedia.org)
  • Acinetobacter species are a key source of infection in debilitated patients in the hospital, in particular the species Acinetobacter baumannii. (wikipedia.org)
  • Species of the genus Acinetobacter are strictly aerobic, nonfermentative, Gram-negative bacilli. (wikipedia.org)
  • citation needed] The morphology of Acinetobacter species can be quite variable in Gram-stained human clinical specimens, and cannot be used to differentiate Acinetobacter from other common causes of infection. (wikipedia.org)
  • The genus Acinetobacter comprises 38 validly named species. (wikipedia.org)
  • Identification of Acinetobacter species is complicated by lack of standard identification techniques. (wikipedia.org)
  • This method allowed identification of A. calcoaceticus-A. baumannii complex by the formation of smooth, rounded, mucoid colonies at 37 °C. Closely related species could not be differentiated and individual species such as A. baumannii and Acinetobacter genomic species 3 could not be positively identified phenotypically. (wikipedia.org)
  • Acinetobacter species are widely distributed in nature, and commonly occur in soil and water. (wikipedia.org)
  • In subgingiva, Acinetobacter and Moraxella species were present only in waterpipe smokers. (who.int)
  • Dozens of Candida species-a group of fungi-cause infections, ranging from mild oral and vaginal yeast infections to severe invasive infections. (cdc.gov)
  • La sensibilité de Staphylococcus aureus à l'oxacilline a diminué significativement, passant de 95,0 % entre 1999 et 2002 à 84,4 % en 2008. (who.int)
  • Roberts S, Chambers S. Diagnosis and management of Staphylococcus aureus infections of the skin and soft tissue. (medscape.com)
  • Immunity against Staphylococcus aureus cutaneous infections. (medscape.com)
  • The effects of these NPs on Acinetobacter baumannii , Staphylococcus aureus , and Escherichia coli biofilms were studied using quantitative biofilm inhibition and disruption assays, as well as using fluorescence, -scanning electron microscopy, and atomic force microscopy. (dovepress.com)
  • Complicated skin and skin structure infections caused by Escherichia coli, Enterococcus faecalis (vancomycin-susceptible isolates only), Staphylococcus aureus (methicillin-susceptible and ‑resistant isolates), Streptococcus agalactiae, Streptococcus anginosus grp. (druglib.com)
  • Complicated intra-abdominal infections caused by Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Enterococcus faecalis (vancomycin-susceptible isolates only), Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus anginosus grp. (druglib.com)
  • The predominant predispositions to infection include colonization pressure, exposure to broad-spectrum antibiotics, and disruption of anatomic barriers. (medscape.com)
  • Critically ill patients with nosocomial infections caused by A. baumannii resistant to all antibiotics except colistin in a medical ICU were included. (biomedcentral.com)
  • Like the more virulent A. baumannii , A. radioresistens is often resistant to multiple antibiotics and can cause catheter-related nosocomial bloodstream infection and community-acquired infection in HIV-positive patients 9 . (nature.com)
  • Dermatologists play an essential role in this process given the significant incidence of inflammatory dermatoses, as well as skin and soft tissue infections (SSTIs) treated with antibiotics. (skintherapyletter.com)
  • citation needed] Most strains of Acinetobacter, except some of the A. lwoffii strain, grow well on MacConkey agar (without salt). (wikipedia.org)
  • This obscure bacterium causes a severe infection for which almost no treatments exist, and mainly affects people who are already critically ill. (bioedonline.org)
  • If diarrhea is severe or lasts more than 2 or 3 days, contact your doctor, as this may be a sign of an infection of the bowels. (rxwiki.com)
  • Zahar JR, Goveia J, Lesprit P, Brun-Buisson C. Severe soft tissue infections of the extremities in patients admitted to an intensive care unit. (medscape.com)
  • It can cause severe infections and spreads easily between hospitalized patients and nursing home residents. (cdc.gov)
  • Tigecycline for the treatment of severe Clostridium difficile infection. (druglib.com)
  • These organisms were the most frequently recovered gram-negative isolate from war wounds and the second most frequent bacterium causing bloodstream infection in US Marines with extremity wounds during the Vietnam War ( 3 ). (cdc.gov)
  • In this report, our team research the Europe Acinetobacter Infections Treatment market by type, application, region and manufacturer 2014-2019 and forcast 2020-2025. (nxtgenreports.com)
  • What would be the total number of patients of Clostridium Difficile Infections across the 7MM during the forecast period (2019-2032)? (marketresearch.com)
  • This observational study retrospectively reviewed the medical records of 1722 intensive care units patients with confirmed healthcare-associated infections at hospitals affiliated with Mashhad University of Medical Sciences in 2017-2019. (who.int)
  • Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. (medscape.com)
  • Clinical and molecular characteristics of invasive and noninvasive skin and soft tissue infections caused by group A Streptococcus. (medscape.com)
  • Comorbidities, skin and soft tissue infections, and infections with Acinetobacter spp. (who.int)
  • Twenty-three soldiers wounded in Iraq and subsequently admitted to our facility from March 2003 to May 2004 had wound cultures positive for Acinetobacter calcoaceticus-baumannii complex. (cdc.gov)
  • Hartsein A. I. , Morthland V. H. , Rourke J. W. Plasmid DNA fingerprinting of Acinetobacter calcoaceticus subspecies anitratus from intubated and mechanically ventilated patients. (microbiologyresearch.org)
  • It also provides treatment algorithms and treatment guidelines for Clostridium Difficile Infections in the US, Europe, and Japan. (marketresearch.com)
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Clostridium Difficile Infections? (marketresearch.com)
  • Despite the drug resistance that infecting organisms demonstrated in this series, a regimen of carefully selected extended antimicrobial-drug therapy appears effective for osteomyelitis caused by MDR Acinetobacter spp. (cdc.gov)
  • Such infections are challenging to treat because of extensive antimicrobial drug resistance. (cdc.gov)
  • Acinetobacter infections have increased and gained attention because of the organism's prolonged environmental survival and propensity to develop antimicrobial drug resistance. (elsevierpure.com)
  • Antibiotic resistance represents an important problem in treating this infection. (univpm.it)
  • Clinical data at ICU admission were collected, as well as the timing of isolation of Acinetobacter baumannii, its resistance profile, the site of infection, and the antibiotic therapy. (univpm.it)
  • Acinetobacter baumannii , carbapenem resistance, fosfomycin. (journalmeddbu.com)
  • Most infections are still sensitive to existing drugs," says Allan Coukell, who oversees an antibiotic-resistance initiative at the Pew Charitable Trusts in Washington DC. (bioedonline.org)
  • Treatments for 'superbug' infections are the focus for innovative research, as drug resistance threatens human health and medical practices globally. (rcsb.org)
  • Trials optimizing timing of antibiotic administration with regard to known antimicrobial pharmacokinetic/pharmacodynamic properties (e.g., prolonging infusion times of β-lactams to reduce bacterial resistance) should also assist in improving outcomes in penetrating traumatic infections, which are increasingly antibiotic resistant. (medscape.com)
  • To investigate the incidence, microbial aetiology, antimicrobial resistance profile, and mortality rate of healthcare- associated infections in intensive care units in the Islamic Republic of Iran. (who.int)
  • Guidelines from the Infectious Diseases Society of America (IDSA) have provided guidance for management of osteomyelitis with prosthetic joints but not for other kinds of orthopedic hardware infections (though extrapolations can be made from the IDSA guidance). (medscape.com)
  • A multidisciplinary guideline development group covering clinical infectious diseases, clinical microbiology, clinical pharmacology, infection control, and guideline methodology experts jointly developed the present clinical practice guidelines based on best available scientific evidence to address the clinical issues regarding laboratory testing, antimicrobial therapy, and prevention of CRGNB infections. (bvsalud.org)
  • We conducted the present observational study to evaluate the efficacy of intravenous and aerosolized colistin combined with rifampicin in the treatment of critically patients with nosocomial infections caused by multiresistant A. baumannii . (biomedcentral.com)
  • infection between 2018 and 2020 receives at least 3 days of oral doxycycline . (bvsalud.org)
  • MethodsSingle-center observational retrospective study, including patients admitted to our ICU from March 2020 to May 2021 for acute respiratory failure from SARS-CoV-2 infection who developed PDR Acinetobacter baumannii superinfection. (univpm.it)
  • The significance of Acinetobacter isolates from clinical specimens, such as respiratory secretions from intubated patients or specimens from open wounds, is difficult to determine because they often represent colonization. (msdmanuals.com)
  • Most Acinetobacter isolates recovered from hospitalized patients, particularly those recovered from respiratory secretions and urine, represent colonization rather than infection. (medscape.com)
  • The presence of Acinetobacter isolates in respiratory secretions of intubated patients may represent colonization. (medscape.com)
  • Infections may complicate continuous ambulatory peritoneal dialysis (CAPD) or cause catheter-associated bacteruria. (medscape.com)
  • Hospital-acquired Acinetobacter pneumonias are frequently multilobar and complicated. (msdmanuals.com)
  • Acinetobacter baumannii is a pleomorphic aerobic gram-negative bacillus (similar in appearance to Haemophilus influenzae on Gram stain) commonly isolated from the hospital environment and hospitalized patients. (medscape.com)
  • In a hospital setting, Acinetobacter commonly colonizes irrigating solutions and intravenous solutions. (medscape.com)
  • Although Acinetobacter is primarily a colonizer in the hospital environment, it occasionally causes infection. (medscape.com)
  • As technology advances to improve health care and reduce hospital-acquired infections, more such hazards may emerge. (cdc.gov)
  • In this study, we investigated the epidemiological and molecular differences of CRAB and the threatening factors for contributing to increased CRAB infections at a hospital in western China. (frontiersin.org)
  • On any given day, about one in 31 hospital patients has at least one healthcare-associated infection. (cdc.gov)
  • is an infection preventionist with the Hospital Infection Prevention Team in the Prevention and Response Branch of CDC's Division of Healthcare Quality Promotion. (cdc.gov)
  • Pelletier J, Gottlieb M, Long B, Perkins JC Jr. Necrotizing Soft Tissue Infections (NSTI): Pearls and Pitfalls for the Emergency Clinician. (medscape.com)
  • Kremer M, Zuckerman R, Avraham Z, Raz R. Long-term antimicrobial therapy in the prevention of recurrent soft-tissue infections. (medscape.com)
  • The risk for infection with MDR organisms appears to depend much more on specific risk factors of the given patient than on contact with various aspects of the healthcare system. (medscape.com)
  • Gram-positive organisms, for example, Streptococcus pyogenes and S. aureus , historically were major causes of morbidity and mortality following penetrating trauma in the pre-antibiotic era and remain initial pathogens for many infection types. (medscape.com)
  • Acinetobacter can cause community-acquired bronchiolitis and tracheobronchitis in healthy children and tracheobronchitis in immunocompromised adults. (msdmanuals.com)
  • Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial. (druglib.com)
  • Acinetobacter baumannii infection presents a high mortality rate and few therapeutic options. (bvsalud.org)
  • Acinetobacter pneumonias occur in outbreaks and are usually associated with colonized respiratory-support equipment or fluids. (medscape.com)
  • Three bundled programmes will be sequentially implemented after a minimum 6-month baseline monitoring period - microbiology and diagnostic stewardship (MDS), infection prevention and control (IPC), and antimicrobial stewardship (ABS). (who.int)
  • Guidelines for the diagnosis, treatment, prevention and control of infections caused by ca. (bvsalud.org)
  • The incidence of bacteremia at military medical facilities caused by Acinetobacter baumannii has also increased ( 2 ). (cdc.gov)
  • We investigated a cluster of postoperative febrile episodes and episodes of Acinetobacter baumannii bacteremia in obstetrics and gynecology wards after an electrical blackout and loss of the water supply. (cambridge.org)
  • and Acinetobacter , see the Healthcare-Associated Infection (HAI) website . (cdc.gov)
  • Healthcare-associated infections are a major cause of mortality worldwide, especially in intensive care units where severely ill patients have limited physical space. (who.int)
  • CI, and to identify univariate and multivariate predictors of healthcare-associated infection mortality. (who.int)
  • Healthcare-associated infections in nearly half of intensive care unit patients were fatal, especially when caused by Acinetobacter spp. (who.int)
  • Candidemia, which is the bloodstream manifestation of fungal infections due to Candida , turns out in recent studies that we've looked at are the most common if not some of the most common healthcare associated bloodstream infections in our country, in the United States. (cdc.gov)
  • These infections are increasingly prevalent and highlylethal, killing 50-60% of those infected. (sbir.gov)
  • HAP is a common nosocomial bacterial infection and is most prevalent in medical and surgical intensive care units (ICUs). (medscape.com)
  • The most common microorganisms were Acinetobacter spp. (who.int)
  • Acinetobacter are gram-negative aerobic bacilli or coccobacilli that belong to the family Moraxellaceae. (msdmanuals.com)
  • This study aims to describe the evolution of the superinfection from PDR Acinetobacter baumannii in patients with acute respiratory failure from SARS-CoV-2 infection admitted to ICU and compare the impact of two different antibiotic strategies on microbiological negativization. (univpm.it)
  • Acute bacterial skin infections and cellulitis. (medscape.com)
  • All infected patients were treated with imipenem, with or without an aminoglycoside, except one patient who died before a diagnosis of acinetobacter infection was confirmed. (microbiologyresearch.org)
  • A retrospective cohort of hospitalized patients with confirmed Acinetobacter spp. (bvsalud.org)
  • The Company, along with our partner Zai Lab (Nasdaq: ZLAB), has enrolled 108 patients with confirmed carbapenem-resistant Acinetobacter infections in the ATTACK trial. (biospace.com)
  • Therefore, since it is a global public health problem involving several sectors, it also requires a global solution in the context of the One Health approach to achieve adequate control through the prevention, reduction, and mitigation of drug-resistant infections. (who.int)
  • Multi-drug resistant (MDR) Acinetobacter baumannii is now a major pathogen responsible for morbidity and mortality in intensive care units. (journalmeddbu.com)
  • Comparison of colistin monotherapy and non-colistin combinations in the treatment of multi-drug resistant Acinetobacter spp. (sdu.edu.tr)
  • Infections with extensively drug-resistant Acinetobacter baumannii (XDRAB) have limited therapeutic options. (edu.au)
  • Although antibiotic treatment is crucial for combating infections, its negative effects on the intestinal microbiota and host immunity have been shown to be of the utmost importance. (mdpi.com)
  • Eighteen had osteomyelitis, 2 burn infection, and 3 deep wound infection. (cdc.gov)
  • Osteomyelitis caused by Acinetobacter occurs, but it is less frequently reported and had not been identified in our facility during the 14 months before March 2003. (cdc.gov)
  • The risk factors for candid are sometimes we call in the fungal world the other C. diff , have somewhat similar characteristics in that broad spectrum antibacterial use is a very common association with those who develop infections due to Candida . (cdc.gov)
  • i.e., systems to promote optimal treatment of infections and appropriate antimicrobial use). (cdc.gov)
  • Cite this: Prophylaxis and Treatment of Infections Associated with Penetrating Traumatic Injury - Medscape - Jan 01, 2011. (medscape.com)
  • DESCRIPTION (provided by applicant): In the last decade, Acinetobacter baumannii has emerged as one of the most highly antibiotic-resistant pathogens in the United States (US) and throughout the world. (sbir.gov)
  • And if you have a new antibiotic, you do really want to hold it in reserve for those resistant infections. (bioedonline.org)
  • The 2013 report stated that each year in the U.S. at least 2 million people got an antimicrobial-resistant infection, and at least 23,000 people died. (cdc.gov)
  • More than 2.8 million antimicrobial-resistant infections occur in the U.S. each year, and more than 35,000 people die as a result. (cdc.gov)
  • When Clostridioides difficile -a bacterium that is not typically resistant but can cause deadly diarrhea and is associated with antibiotic use-is added to these, the U.S. toll of all the threats in the report exceeds 3 million infections and 48,000 deaths. (cdc.gov)
  • Acinetobacter baumannii has emerged as a pan-resistant superbug causing fatal infections in vulnerable patients. (usp.br)
  • Alternative therapy for resistant Acinetobacter infection is currently the subject of intense interest and research. (usp.br)
  • Multiple factors tend to increase the risk of acquiring an Acinetobacter infection, including prior antibiotic exposure, intensive care unit admission, use of a central venous catheter, and mechanical ventilation or hemodialysis use. (medscape.com)
  • Acinetobacter commonly colonizes patients in the intensive care setting. (medscape.com)
  • Beck-Sagué C. M. , Jarvis W. R. , Brook J. H. Epidemic bacteriemia due to Acinetobacter baumannii in five intensive care units. (microbiologyresearch.org)
  • The intensive care units (ICUs), in particular, are hotbeds for contracting infections ( 5 ). (who.int)
  • The current incidence of infection with Acinetobacter should not be surprising. (cdc.gov)
  • Include information on changes in prevalence or incidence of infection, results of assessments for system failures, and action plans to improve adherence to and effectiveness of recommended infection control practices to prevent MDRO transmission. (cdc.gov)
  • AB infections typically occur in critically ill, hospitalized patients. (msdmanuals.com)
  • When Acinetobacter causes actual infection, the pathological changes that occur depend on the organ system involved. (medscape.com)
  • Acinetobacter infections are uncommon and occur almost exclusively in hospitalized patients. (medscape.com)